Jefferies backs Lupin, Zydus, and Biocon amid shifting US pharma market shares. Discover why these stocks are set to shine.

The discussions emphasised the evolving landscape of acute liver failure, sepsis in chronic liver disease, and post-transplant critical care The Tribune, now published from Chandigarh, started ...

The study by Ma et al. provides fundamental findings and compelling evidence that Pyrotinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (PERSIST): A ...

This study provides valuable insights into the efficacy and safety of pyrotinib as an extended adjuvant therapy following trastuzumab-based treatment in patients with high-risk HER2-positive breast ...

Zydus Lifesciences has launched VaxiFlu-4, India’s first quadrivalent flu vaccine to offer better protection against influenza A and B strains. Experts stress the importance of vaccination and ...

Zydus Lifesciences on Wednesday said it is introducing a vaccine for protection against a new strain of influenza virus. The company is introducing the country’s first flu protection quadrivalent ...

1Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas. Search for other works by this author on: 1Department of Investigational Cancer ...

Zydus Lifesciences on Wednesday (February 26, 2025) said it is introducing a vaccine for protection against new strain of influenza virus. “The company is introducing country’s first flu ...

Ahmedabad-based Zydus Lifesciences is set to launch the vaccine VaxiFlu-4 to combat a new strain of the influenza virus, as per the WHO-recommended composition of quadrivalent influenza virus ...

Indian pharma industry is capable of delivering 100 new drugs by 2047 for global markets backed by enhanced research and development efforts, Zydus Lifesciences Chairman Pankaj R Patel said on Friday.

Zydus Lifesciences Chairman Pankaj R Patel believes India can deliver 100 new drugs by 2047, emphasizing the need for innovation and societal benefit. Read more. New Delhi, Feb 21 (PTI) Indian pharma ...

and Zydus Lifesciences hit their 52-week lows in intraday trade on BSE on Wednesday, February 19, on the backdrop of conflicting global signals and uncertainties regarding the US tariffs that were ...